Edition:
United States

Prothena Corporation PLC (PRTA.OQ)

PRTA.OQ on NASDAQ Stock Exchange Global Select Market

13.03USD
17 Oct 2018
Change (% chg)

$-0.02 (-0.15%)
Prev Close
$13.05
Open
$13.01
Day's High
$13.27
Day's Low
$12.01
Volume
117,212
Avg. Vol
187,144
52-wk High
$62.93
52-wk Low
$10.44

Latest Key Developments (Source: Significant Developments)

Prothena Announces Global Neuroscience Research & Development Collaboration With Celgene
Tuesday, 20 Mar 2018 04:05pm EDT 

March 20 (Reuters) - Prothena Corporation Plc ::PROTHENA ANNOUNCES GLOBAL NEUROSCIENCE RESEARCH & DEVELOPMENT COLLABORATION WITH CELGENE FOR NOVEL THERAPIES FOR PATIENTS WITH NEURODEGENERATIVE DISEASES.PROTHENA CORPORATION - PROTHENA TO RECEIVE A $100 MILLION UPFRONT PAYMENT AND A $50 MILLION EQUITY INVESTMENT BY CELGENE.PROTHENA CORPORATION- COLLABORATION INCLUDES POTENTIAL LICENSE PAYMENTS, MILESTONES, PLUS ADDITIONAL ROYALTIES ON SALES FROM LICENSED PROGRAMS FOR CO.PROTHENA CORPORATION PLC - CELGENE WILL SUBSCRIBE TO ABOUT 1.2 MILLION OF PROTHENA'S ORDINARY SHARES AT $42.57 PER SHARE.  Full Article

Prothena Corp Files For Potential Stock Shelf Offering
Monday, 26 Feb 2018 07:42am EST 

Feb 26 (Reuters) - Prothena Corporation Plc ::PROTHENA CORPORATION PLC FILES FOR POTENTIAL STOCK SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Prothena Q4 Loss Per Share $1.24
Wednesday, 14 Feb 2018 04:05pm EST 

Feb 14 (Reuters) - Prothena Corporation Plc ::PROTHENA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS, AND PROVIDES FINANCIAL GUIDANCE AND RESEARCH AND DEVELOPMENT UPDATE.Q4 LOSS PER SHARE $1.24.Q4 REVENUE $200,000.AS OF DECEMBER 31, 2017, PROTHENA HAD $421.7 MILLION IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND NO DEBT.EXPECTS THE FULL YEAR 2018 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES TO BE $175 TO $230 MILLION.Q4 EARNINGS PER SHARE VIEW $-1.48, REVENUE VIEW $237600.00 -- THOMSON REUTERS I/B/E/S.  Full Article

Prothena reports Q3 loss per share $1.37
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Prothena Corporation Plc ::Prothena reports third quarter 2017 financial results and provides research and development update.Q3 loss per share $1.37.Q3 revenue $200,000.Q3 revenue view $251,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article

Prothena reports third quarter financial results
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Prothena Corporation Plc :Prothena reports third quarter 2017 financial results and provides research and development update.Q3 loss per share $1.37.Q3 revenue $200,000.Q3 revenue view $251,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article

Prothena reports Q2 loss per share $0.46
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 9 (Reuters) - Prothena Corporation Plc -:Prothena reports second quarter 2017 financial results and provides research and development update.Q2 loss per share $0.46.Q2 revenue $26.8 million.Q2 revenue view $15.1 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.88 -- Thomson Reuters I/B/E/S.Prothena Corporation Plc - ‍as of june 30, 2017, prothena had $475.8 million in cash, cash equivalents and restricted cash and no debt.​.Prothena Corporation Plc - ‍expects full year 2017 net cash burn from operating and investing activities to be $160 to $170 million​.  Full Article

Prothena Q2 loss per share $0.46
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Prothena Corporation Plc :Prothena reports second quarter 2017 financial results and provides research and development update.Q2 loss per share $0.46.Q2 revenue $26.8 million.Q2 revenue view $15.1 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.88 -- Thomson Reuters I/B/E/S.Prothena Corporation PLC says we expect topline results from phase 1B mad study of PRX003 in patients with psoriasis in october.Prothena Corporation PLC says expect topline results from phase 2b pronto study of neod001 in patients with al amyloidosis in q2 of 2018.  Full Article

Prothena reports Q1 2017 financial results
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Prothena Corporation PLC ::Prothena Corporation PLC says expects full year 2017 net cash burn from operating and investing activities to be $160 to $170 million.Reports first quarter 2017 financial results and provides research and development update.Q1 loss per share $0.99.Q1 revenue $300,000 versus i/b/e/s view $261,000.Q1 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article

Prothena reports Q1 loss per share $0.99
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Prothena Corporation Plc :Prothena reports first quarter 2017 financial results and provides research and development update.Q1 loss per share $0.99.Q1 revenue $300,000 versus I/B/E/S view $261,000.Q1 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.Prothena Corporation Plc - company expects full year 2017 net cash burn from operating and investing activities to be $160 to $170 million.  Full Article

Prothena Corp, Prothena Biosciences enter letter agreement with Boehringer Ingelheim
Wednesday, 12 Apr 2017 06:48am EDT 

Prothena Corporation Plc : Prothena Corporation - on April 5, 2017, co and Prothena Biosciences entered letter agreement with Boehringer Ingelheim Biopharmaceuticals GMBH . Prothena Corp - Boehringer Ingelheim reserved for Prothena capacity to manufacture and supply bulk drug substance of NEOD001, PRX003, possibly additional biologics .Prothena Corp - under agreement, Prothena made commitments for purchase of products from Boehringer Ingelheim.  Full Article